Category: General Biotechnology

Drug Patent Expirations in April 2007

Courtesy of DrugPatentWatch.com: Drug Patent Expirations in April 2007*Drugs may be covered by more than one patent Tradename Applicant Generic Name Patent Number Patent Expiration AMBIEN Sanofi Aventis Us zolpidem tartrate 4,382,938 APR 21,2007 AMBIEN CR Sanofi Aventis Us zolpidem tartrate 4,382,938 APR 21,2007 BIDIL Nitromed hydralazine hydrochloride; isosorbide dinitrate 4,868,179 APR 22,2007 DEPAKOTE ER […]




Click here for reuse options!
Copyright 2007 Biotechblog

Genentech goes offshore

Genentech is investing $140mm in a new biologic manufacturing plant in Singapore. The first commercial-scale microbial fermentation plant in Singapore, and a significant International investment by US-based Genentech. This is the latest of a number of international manufacturing and R&D centers being located in Singapore, and is a sign of the growing trend of biotechnology […]




Click here for reuse options!
Copyright 2007 Biotechblog

Patent licensees gain more power

I touched briefly on the Medimmune v. Genentech case in a previous Carnival of Biotechnology, but I didn’t go into great detail on the case because I didn’t want to scoop David Morrill who interviewed me for an article on the case. You can read my thoughts in David’s article, but I’ll go ahead and […]




Click here for reuse options!
Copyright 2007 Biotechblog

Carnival of Biotechnology

The latest Carnival of Biotechnology is up at Baby Biotechs. Great job, Brian! For more information, see the Carnival of Biotechnology Homepage, or submit a link for the next edition. Interested in hosting a future Carnival of Biotechnology? Let me know.




Click here for reuse options!
Copyright 2007 Biotechblog

Xenotourism: Scary Stuff

Just came across an article on diabetics going to Mexico to receive pig xenotransplants. Unlike other forms of medical tourism, where patients travel to other countries for lower cost treatments, better quality treatments, or to receive ethically questionable organ transplants, xenotransplantation carries significant safety concerns. Xenotransplantation is the transplantation of organs or tissues from non-humans […]




Click here for reuse options!
Copyright 2007 Biotechblog

The commercial prospects of biogenerics – how much will they save?

This follow-up to my post on the technical reasons why biogenerics are so hard to regulate provides some updates the status of biogenerics, background on the key issues, and the impacts on the industry of the various possible approval schemes. Clinical Trials The clinical trial requirement for biogenerics is the leading issue from a regulatory […]




Click here for reuse options!
Copyright 2007 Biotechblog

VCs filling biotech funding gap

If there’s one sure rule about private equity, it is that there are no rules about private equity! Venture capitalists will tell you that they have different investment philosophies than everyone else, they’ll tell you that they’re not venture capitalists, they’ll tell you that they focus on areas that everyone else ignores. So, it should […]




Click here for reuse options!
Copyright 2007 Biotechblog

Angels filling biotechnology funding gap

Biotechnology companies have been facing a widening funding gap. Between frozen federal research budgets and a growing focus among venture capitalists and senior partners for larger, more mature, biotechnology firms – at the expense of smaller ones – a funding gap is growing between basic research and initial proof-of-principle commercial research. So, who fills the […]




Click here for reuse options!
Copyright 2007 Biotechblog

Looking beyond traditional markets

The United States is the world’s largest pharmaceutical market. Japan is the second largest, although the combined European Union is larger than the Japanese market (but smaller than the U.S.). Naturally, any company looking to sell drugs should focus on these markets, but there are reasons to reach out into smaller markets: This article describes […]




Click here for reuse options!
Copyright 2007 Biotechblog

Price controls and compulsory licensing give buyers more power … for a price.

Countries use various methods to control drug expenditures. Beyond simple negotiation, countries can also implement price controls or use WTO-authorized compulsory licensing, which enables a country to produce generic versions of branded drugs if they face a health crisis without violating international patent agreements. The United States threatened to use compulsory licensing to acquire cheap […]




Click here for reuse options!
Copyright 2007 Biotechblog

%d bloggers like this: